Skip to main content

Animations

Krystof Bankiewicz, MD, PhD

Kinetics Foundation Chair in Translational Research, and Professor in Residence of Neurosurgery and Neurology, and Director of the Translational NeuroTherapy Center at University of California, San Francisco

/* Style Definitions */ table.MsoNormalTable {mso-style-name:"Table Normal"; mso-tstyle-rowband-size:0; mso-tstyle-colband-size:0; mso-style-noshow:yes; mso-style-priority:99; mso-style-parent:""; mso-padding-alt:0in 5.4pt 0in 5.4pt; mso-para-margin:0in; mso-para-margin-bottom:.0001pt; mso-pagination:widow-orphan; font-size:10.0pt; font-family:"Times New Roman","serif";}

Dr. Bankiewicz is the Kinetics Foundation Chair in Translational Research, Professor in Residence of Neurosurgery and Neurology and Director of the Translational NeuroTherapy Center at University of California, San Francisco (UCSF).

Dr. Bankiewicz received MD degree from Jagiellonian University in Crakow and PhD and DSc degrees from the Institute of Neurology and Psychiatry in Warsaw, Poland. He trained as Fogarty Fellow at Surgical Neurology Branch of the NINDS at the NIH in Bethesda, Maryland. Throughout his career, he has maintained a strong focus on the development of translational approaches to gene and cell replacement therapies, and has displayed a remarkable ability to synthesize several individual technologies into powerful new approaches to the treatment of brain cancer and neurodegenerative disorders of the brain, including Parkinson's, Huntington’s, Alzheimer’s diseases, pediatric neurotransmitter deficiency and lysosomal storage disorders.

Dr. Bankiewicz is an inventor of numerous patents, has published more than 180 peer-reviewed research articles, is a member of several Editorial and Scientific Advisory Boards of many biotech and pharma companies. Dr. Bankiewicz has considerable experience in supervising multi-investigator translational programs. He has supervised a total of 25 post-doctoral fellows, and manages a core research group of over 20 individuals including technicians, post-doctoral fellows, and senior scientists. Dr. Bankiewicz was instrumental at every stage of the clinical trials for AAV2-hAADC and AAV2-hGDNF gene therapy for Parkinson’s Disease. He continues to champion the development of novel therapeutic strategies to treat Parkinson’s Disease.


Associated Grants

  • Phase I Study of AAV2-hAADC Administered by MRI-guided Real-time Convective Infusion

    2012


  • Image-Guided Convective Delivery of AAV Vectors

    2008


  • Development and Optimization of a Regulatable Gene Switch for Gene Therapies of Parkinson’s Disease

    2005


We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.